Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Paclitaxel (DHP107) vs IV Paclitaxel in First-line Treatment of Recurrent or Metastatic HER2-negative Breast Cancer
2020-000954-86Phase 3Active
- Sponsor
- Daehwa Pharmaceutical Co., Ltd.
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel in breast cancer (2 arms), sponsored by Daehwa Pharmaceutical Co., Ltd. Primary endpoint: Progression-free survival. Started Jun 2020; status: active.
02
Drugs
paclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2020-000954-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000954-86.